CapsoVision, Inc.

CV Healthcare Medical Devices

CapsoVision, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 15.3% from fiscal 2024. In the quarter to June 2026, revenue grew 9.89%, EPS grew 92.6% and free cash flow fell 84.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.53 0.08 +1.24%
Market cap
$343.2M
P/E
2.1×
Fwd P/E
−13.8×
Dividend yield
—
F-score
n/a
Altman Z
17.04
Beneish M
−3.47
Dividend safety
n/a
Dec '25 Dec '24
P/E ratio
0.00 0.00
Altman Z-Score
17.04 —
P/S ratio
19.37 0.67
Altman Z″-Score (non-manufacturers)
(30.12) (29.09)
P/FCF ratio
0.00 0.00
Beneish M-Score
(3.47) —
P/Operating CF
(34.15) (1.77)
P/B ratio
19.80 0.00
EV/Sales
18.62 0.58
EV/EBITDA
0.00 0.00
EV/FCF
(11.00) (0.32)
Current Ratio
3.77 8.24
Net Debt/EBITDA
0.41 0.48
Debt/Equity
0.00 0.00
ROE
43.55% 0.00%
ROA
(144.79%) 0.00%
ROIC
(506.59%) 0.00%
Return on Tangible Assets
(196.96%) (144.54%)
Average Days of Receivables
67.27 62.13
Earnings Yield
(9.65%) (282.26%)
Free Cash Flow Yield
(8.74%) (274.76%)
Free Cash Flow per Share
(0.93) (10.02)
Book value per Share
0.54 (64.11)
Free Cash Flow
(22.95) (20.24)
EV/EBIT
0.00 0.00
Other line items

Show all line items

Columns are period end dates